notice received, page-12

Ha-ha yeah it's an interesting situation at the moment.

I've been following this stock for years, and have bought/ sold multiple times. Long/short.

It appears to be a good long term buy, regardless of what is said by the FDA. However short term it appears more of short.

Like I said, it seems unusual for so much stock to be available on the short side( with 180mil market cap DMA providers would usually struggle to still find stock to borrow). However at the moment you can currently sell big units while only putting down an initial margin of 25%.